Hepadnaviridae Infections is an indication for drug development with over 250 pipeline drugs currently active. According to GlobalData, preregistered drugs for Hepadnaviridae Infections have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Hepadnaviridae Infections compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Hepadnaviridae Infections overview

Hepadnaviridae infections are caused by a family of viruses that infect the liver of various animals, such as birds, mammals, reptiles and fish. The most well-known member of this family is hepatitis B virus (HBV), which can cause chronic liver disease and cancer in humans. Hepadnaviruses have a partially double-stranded DNA genome that replicates by reverse transcription within the cytoplasm of infected cells. The genome encodes four genes: core, polymerase, surface and X. The core gene produces the nucleocapsid protein and a secreted antigen (HBeAg). The polymerase gene encodes the reverse transcriptase and the DNA polymerase. The surface gene produces three envelope proteins (preS1, preS2 and S) that mediate viral entry and assembly. The X gene encodes a regulatory protein that modulates host gene expression and cell signaling. Hepadnaviruses are classified into five genera: Orthohepadnavirus, Avihepadnavirus, Herpetohepadnavirus, Metahepadnavirus and Parahepadnavirus, based on their host range, genome organization and phylogenetic relationships.

For a complete picture of PTSR and LoA scores for drugs in Hepadnaviridae Infections, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.